Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
EJNMMI Radiopharmacy and Chemistry|November 28, 2024
Lead-it-EAZY! GMP-compliant production of [212Pb]Pb-PSC-PEG2-TOCMarc Pretze, Enrico Michler, David Kästner, et al.
Toxics|June 25, 2025
Different 212Pb Generators and Its Radiation Safety Concerning 220Rn (Thoron) EmanationMarc Pretze, Holger Hartmann, Charlotte Duchemin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 13, 2023
Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumorsDongyoul Lee, Mengshi Li, Dijie Liu, et al.
Cancers|August 7, 2021
Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant MelanomaMengshi Li, Dijie Liu, Dongyoul Lee, et al.
Molecular Pharmaceutics|July 19, 2019
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic MelanomaMengshi Li, Dijie Liu, Dongyoul Lee, et al.
Current Medicinal Chemistry|July 29, 2020
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for CancerMengshi Li, Edwin A Sagastume, Dongyoul Lee, et al.
Pharmaceutics|February 25, 2023
Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based TheranosticsMengshi Li, Nicholas J Baumhover, Dijie Liu, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Pre-clinical Evaluation of Biomarkers for Early Detection of Nephrotoxicity Following Alpha-particle Radioligand TherapyMengshi Li, Claudia Robles-Planells, Dijie Liu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 14, 2023
Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapyMengshi Li, Claudia Robles-Planells, Dijie Liu, et al.
Pageof 1